Key Trends Influencing the Growth of the Cancer Gene Therapy Market in 2025: Breakthrough In Affordable Personalized Cancer Treatment Through Advanced Cell Therapy

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Is the Expected CAGR for the Cancer Gene Therapy Market Through 2025?
In the past few years, there has been a significant increase in the size of the cancer gene therapy market. This market is expected to expand from a value of $3.61 billion in 2024 to approximately $4.21 billion in 2025, equivalent to a compound annual growth rate (CAGR) of 16.6%. The growth observed in the historic period can be linked to a heightened awareness of cancers related to oncoviruses, increased partnerships between biotech companies and academic entities, an upsurge in early-phase gene therapy clinical trials, burgeoning demand for ex vivo modified cell therapies, as well as a notable increase in strategic licensing deals involving gene therapy platforms.

What's the Projected Size of the Global Cancer Gene Therapy Market by 2029?
The market for cancer gene therapy is projected to witness substantial growth in the upcoming years, with its size likely to reach $7.67 billion by 2029, growing at a Compound Annual Growth Rate (CAGR) of 16.2%. The escalation in this forecast period can be linked to an increased spotlight on non-viral delivery systems, the enlarging presence of companion diagnostics, burgeoning interest in off-the-shelf allogeneic cell therapies, expanding operations of contract development & manufacturing organizations (CDMOs), and advancements in synthetic biology that allows for the customization of gene circuits. Key trends expected during the forecast period encompass progress in non-viral gene delivery platforms, enhancement of manufacturing automation for gene therapy production, the evolution of synthetic promoters for cancer-specific expression, novel approaches in intratumoral gene therapy application, and the creation of multiplexed gene modulation strategies.

View the full report here:
https://www.thebusinessresearchcompany.com/report/cancer-gene-therapy-global-market-report

Top Growth Drivers in the Cancer Gene Therapy Industry: What's Accelerating the Market?
The rise in cancer cases is anticipated to boost the expansion of the cancer gene therapy market in the future. Cancer, a condition defined by the unchecked proliferation of abnormal cells that have the potential to infiltrate and metastasize to other body areas, stems from different tissues and organs and is classified according to the type of cell or tissue from which it develops. The increasing longevity of life is contributing to the growth in cancer cases, as the probability of contracting cancer escalates with age. Cancer gene therapy works by altering or substitifg faulty genes to halt the expansion of cancer cells or bolster the immune system's capacity to eradicate them. For example, in August 2024, more than 3 million individuals in the UK were reported to be living with cancer, according to Macmillan Cancer Support, a UK-based establishment. This number is estimated to escalate to 3.5 million by 2025, 4 million by 2030, and 5.3 million by 2040. Consequently, the escalating incidence of cancer is fueling the expansion of the cancer gene therapy market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=27233&type=smp

Which Emerging Trends Are Transforming the Cancer Gene Therapy Market in 2025?
Leading enterprises in the cancer gene therapy market are making strides in the production of innovative therapies such as CAR-T cell therapy. Their aim is to increase the precision of treatment, boost patient survival rates, and efficiently target cancerous cells while preserving healthy tissue. CAR-T therapy is a sophisticated form of immunotherapy where the patient's immune cells are altered to detect and kill cancer cells more effectively by adding specific receptors. For example, ImmunoACT, a biotechnology firm based in India, introduced NexCAR19 (actalycabtagene autoleucel), India's first locally produced CAR-T cell cancer therapy, in April 2024. This therapy, specifically created for B-cell lymphomas and leukemias, reprograms a patient's T cells to recognize and eliminate cancer cells. Leveraging advanced chimeric antigen receptor (CAR) technology, the therapy is produced domestically, making it more affordable and readily available than imported options. This significant launch signifies India's significant step into the international cancer gene therapy market, underscoring substantial advancements in local innovation and the personalization of cancer treatment.

What Are the Main Segments in the Cancer Gene Therapy Market?
The cancer gene therapy market covered in this report is segmented

1) By Therapy: Gene Induced Immunotherapy, Oncolytic Virotherapy, Gene Transfer
2) By Indication: Large B-Cell Lymphoma, Multiple Myeloma, Acute Lymphoblastic Leukemia (ALL), Melanoma (lesions), Other Indications
3) By Vector Type: Lentivirus, RetroVirus And Gamma RetroVirus, Adeno-Associated Virus (AAV), Modified Herpes Simplex Virus, Adenovirus, Other Vector Types
4) By End-User: Hospitals, Research Institutes, Biopharma Companies, Diagnostic centers, Other End Users

Subsegments:
1) By Gene Induced Immunotherapy: CAR-T Cell Therapy, TCR (T-Cell Receptor) Therapy, Tumor-Infiltrating Lymphocyte (TIL) Therapy, Dendritic Cell-Based Gene Therapy, NK Cell Gene Therapy
2) By Oncolytic Virotherapy: Adenoviruses, Herpes Simplex Virus (HSV), Reovirus, Vaccinia Virus, Newcastle Disease Virus (NDV)
3) By Gene Transfer: Viral Gene Transfer, Non-Viral Gene Transfer

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=27233&type=smp

Which Top Companies are Driving Growth in the Cancer Gene Therapy Market?
Major companies operating in the cancer gene therapy market are Bristol Myers Company, Novartis AG, GSK plc., Gilead Sciences Inc., Amgen Inc., Orchard Therapeutics Plc, Biogen Inc., Sarepta Therapeutics Inc., AGC Biologics, Adaptimmune Limited, Sibiono, Elevate Bio Inc., Bluebird Bio Inc., Uniqure N.V., Shanghai Sunway Biotech Co. Ltd., Anges Inc., Gensight Biologics, Genelux Corporation, Cellectis, and Abeona Therapeutics Inc.

Which Regions Will Dominate the Cancer Gene Therapy Market Through 2029?
North America was the largest region in the cancer gene therapy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer gene therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=27233

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Saumya Sahey
Europe: +44 7882 955267,
Asia: +44 7882 955267 & +91 8897263534,
Americas: +1 310-496-7795
Email: saumyas@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.